Cannabis for inflammatory bowel disease: animal models are promising but human trials have not shown efficacy | Research

The takeaway

Animal models show cannabinoids can improve intestinal inflammation, but randomized controlled trials in IBD patients have not demonstrated efficacy for reducing inflammatory disease activity. Cannabis may help with symptom management.

IBD patients considering cannabis, gastroenterologists, and medical cannabis researchers.

RCTs have not shown cannabis reduces IBD inflammation

What the researchers found

In animal models, cannabinoids improved intestinal inflammation through the endocannabinoid system. However, the few randomized controlled trials of cannabis or CBD in IBD patients failed to show efficacy for modifying inflammatory disease activity. Cannabis may still be effective for symptomatic management (pain, appetite, nausea).

Why it matters

Many IBD patients use cannabis for symptom relief, and cultural acceptance is growing. Clinicians need to understand the gap between promising animal data and disappointing human trial results.

The numbers in context

Animal models showed improvement in experimental IBD. Few RCTs conducted; none demonstrated efficacy for inflammatory disease activity.

How the study worked

Narrative review of preclinical and clinical data on cannabis and cannabinoids in IBD management.

What this study cannot tell us

Narrative review. Very few RCTs exist to draw from. The distinction between symptomatic relief and disease modification is critical but hard to study.

How to read the evidence

Moderate: narrative review integrating animal and human data, limited by the small number of existing RCTs.

When this study was published

Published in 2019.

The bigger picture

IBD patients are among the most common self-medicators with cannabis. This review highlights that while cannabis may help patients feel better symptomatically, it does not appear to be addressing the underlying inflammation.

Questions still open

Could specific cannabinoid formulations or delivery methods prove more effective? Is there a role for cannabis as adjunctive therapy alongside standard IBD treatments? Does symptomatic improvement without inflammatory control pose long-term risks?

Common questions

Does cannabis help with Crohn's or ulcerative colitis?

It may help with symptoms like pain, nausea, and appetite, but clinical trials have not shown it reduces the underlying intestinal inflammation that defines these diseases.

Should IBD patients stop using cannabis?

This review does not make treatment recommendations. It notes that cannabis may provide symptomatic relief even if it doesn't modify disease activity, and that physicians should be aware of its limitations.

Read the original research

Insights into the role of cannabis in the management of inflammatory bowel disease.

Therapeutic advances in gastroenterology, 12, 1756284819870977

View on PubMed ↗Publisher’s paper ↗

Citation

Picardo, Sherman; Kaplan, Gilaad G; Sharkey, Keith A; Seow, Cynthia H. (2019). Insights into the role of cannabis in the management of inflammatory bowel disease.. Therapeutic advances in gastroenterology, 12, 1756284819870977. https://doi.org/10.1177/1756284819870977